The safety and tolerability of methotrexate for treating patients with Crohns disease

Journal of Clinical Gastroenterology

Volumn 45, Issue 7, 2011, Pages 599-601

  Chande, Nilesh ^a   Abdelgadir, Ibrahim ^a   Gregor, James ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Crohns disease; drug induced liver disease; inflammatory bowel disease; methotrexate

Indexed keywords

AZATHIOPRINE; METHOTREXATE;

ARTICLE; BLOATING; CHEMOTHERAPY INDUCED EMESIS; CROHN DISEASE; DIARRHEA; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NAUSEA; PANCYTOPENIA; PRIORITY JOURNAL; PRURITUS; REMISSION; SIDE EFFECT; TREATMENT DURATION;

ADULT; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; MALE; METHOTREXATE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79960600311     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181f593f9     Document Type: Article

References (23)

1. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohns Disease Study: results of drug treatment. Gastroenterology. 1979;77(4 Pt 2):847-869 (Pubitemid 9242048)
2. Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohns Disease Study: results of drug treatment. Gastroenterology. 1984;86:249-266 (Pubitemid 14218578)
3. Binder V, Hendriksen C, Kreiner S. Prognosis in Crohns disease-based on result from a regional patient group from the country of Copenhagen. Gut. 1985;26:146-150 (Pubitemid 15105140)
4. Ward JR. Historical perspective on the use of methotrexate for the treatment of rheumatoid arthritis. J Rheumatol Suppl. 1985;12(suppl 12):3-6 (Pubitemid 16082371)
5. Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp Dermatol. 1996;21:399-408 (Pubitemid 27198662)
6. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989; 110:353-356 (Pubitemid 19073651)
7. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohns disease. The North American Crohns Study Group Investigators. N Engl J Med. 1995;332:292-297
8. Oren R, MoshkowitzM, Odes S, et al. Methotrexate in chronic active Crohns disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol. 1997;92:2203-2209
9. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohns disease: results of a randomized, double-blind, placebocontrolled trial. Hepatogastroenterology. 1999;46:1724-1729
10. Mate-Jimenez J, Hermida C, Cantero-Perona J, et al. 6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12: 1227-1233
11. Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohns disease: a randomised, investigatorblind study. Dig Liver Dis. 2003;35:619-627 (Pubitemid 41110872)
12. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohns disease. North American Crohns Study Group Investigators. N Engl J Med. 2000;342:1627-1632 (Pubitemid 30341531)
13. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohns disease. Cochrane Database Syst Rev. 2005;1:CD003459
14. Patel V, MacDonald JK, McDonald JW, et al. Methotrexate for maintenance of remission in Crohns disease. Cochrane Database Syst Rev. 2009;4:CD006884
15. Chande N, Ponich T, Gregor J. A survey of Canadian gastroenterologists about the use of methotrexate in patients with Crohns disease. Can J Gastroenterol. 2005;19:553-558 (Pubitemid 41582323)
16. Whiting-OKeefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991;90:711-716
17. Roenigk HH Jr, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998; 38:478-485 (Pubitemid 28125534)
18. Lémann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohns disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000;95:1730-1734 (Pubitemid 30485010)
19. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of longterm methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95:3150-3156
20. Balis FM, Mirro J Jr, Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol. 1988;6:1882-1886 (Pubitemid 19089072)
21. Egan LJ, Sandborn WJ, Mays DC, et al. Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Clin Pharmacol Ther. 1999;65: 29-39 (Pubitemid 29062026)
22. Feagan BG, Alfadhli A. Methotrexate in inflammatory bowel disease. Gastroenterol Clin North Am. 2004;33:407-420, xi (Pubitemid 38737279)
23. Kremer J, Alarcon G, Lightfoot R, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum. 1994;37:316-328 (Pubitemid 24093622)